

CURRICULUM VITAE

Dr Costas Oxynos

MB BS (London), MRCP (London), CCST(UK), M.D.

Dr Costas Oxynos studied Medicine at Kings College London, (MBBS degree, 1994) and subsequently undertook General Professional Training in London and Manchester (MRCP London UK, 1998). He subsequently underwent Higher Medical Training in Endocrinology / Diabetes and General Internal Medicine in Manchester/ Leeds UK, (CCST, 2004). During his Higher Medical Training he undertook full time research In Endocrinology/Andrology in Manchester, (Lecturer in Medicine) and was awarded an MD by the University of Manchester (2004). In 2004, he was appointed Consultant in Endocrinology/ Diabetes and General Internal Medicine, in Newcastle UK. In 2007, he moved to Nicosia Cyprus. Since then he is a Consultant in Endocrinology-Diabetes and General Internal Medicine at Apollonio University Hospital . He is also Lead Clinical Tutor in Medicine. In 2017 he was appointed Associate Professor of Endocrinology at the University of Nicosia /Saint George's University of London Medical Programme.

His sub-specialty interests include Diabetes (& microvascular complications), thyroid cancer, osteoporosis, and male hypogonadism.

PERSONAL DETAILS

Name: **Dr. Costas OXYNOS.**
Date of Birth: 27 September 1968.
Nationality: British & Cypriot.
Address: Apollonio Hospital, Nicosia, Cyprus.
Tel no.: 22469248, 22469000
E mail: c.oxynos@googlemail.com

CURRENT POSITION: 2007-

Consultant in Endocrinology/Diabetes and General Internal Medicine, Apollonio University Hospital, Nicosia, Cyprus. Assoc Professor Endocrinology (/Univ. of Nicosia/ St Georges London Medical Programme).

Outpatient clinics: Endocrine, Thyroid, Diabetes (General and Antenatal), Antenatal Endocrine. Inpatient : General medical ward, Responsible for Hospital Medical Staff Educational Programme/Training Seminars Undergraduate Teaching: T (2nd) year student Clinical Lead Tutor on the St Georges University of London Medical Programme at the University of Nicosia.

Other duties: Vice President of Cyprus Endocrine Society, President of MRCA-Cy (Medical Royal Colleges Association-Cyprus), Advisory Panel Member for Endocrinology & Diabetes to Department of Health Cyprus.

GMC (General Medical Council, London, UK) Specialist Registration No.: 4105198
Cyprus Medical Council no. 2493/2008

MEDICAL QUALIFICATIONS

1. **CCST (UK)** (Certificate Completion Specialist Training) In Endocrinology, Diabetes and Internal Medicine. 2004
2. **M.D. (Doctorate in Endocrinology/Andrology).** Degree of Doctor of Medicine. University of Manchester. 2004.
3. **MRCP (LONDON.)**, General Medicine, (Membership of the Royal College of Physicians of London, UK). 1998.
4. **MBBS** (Bachelor of Medicine, Bachelor of Surgery), King's College School of Medicine and Dentistry, London University, 1994.

SUBSPECIALTY TRAINING COURSES in Thyroid Ultrasound

Boston USA, 2007
London, 2006

PROFESSIONAL EXPERIENCE AS SPECIALIST (UNITED KINGDOM).

CONSULTANT

- *Queen Elizabeth Hospital: Gateshead Health NHS Foundation Trust, Newcastle.* Consultant in Endocrinology/ Diabetes and General Internal Medicine 2004-07.
- Specialist Registrar in Endocrinology / Diabetes and GIM. Leeds Teaching Hospitals NHS Trust, 2001-2004
- University of Manchester: Lecturer in Endocrinology Sep '99 - Feb '01
Manchester Royal Infirmary Full time research leading to M.D (Medical Doctorate) in Endocrinology.
- Specialist Registrar in Endocrinology / Diabetes and GIM. Queen Margaret Hospital NHS Trust, Dunfermline, Fife: Jan '99-Sep '99

GENERAL PROFESSIONAL TRAINING EXPERIENCE. (UNITED KINGDOM).

- Withington Hospital (S. Manchester University Hospitals NHS Trust / Christie Hospital NHS Trust, 1997-1998
- Chase Farm Hospital, London): Chase Farm Hospital: 1995-1996
- King's College Hospital (London): 1994-1995

ACADEMIC PUBLICATIONS: (First Author)

1. **C Oxynos.** Testosterone treatment in male hypogonadism. Review. CME Endocrinology & Diabetes Vol 5 (2), pg 43-46 (2005).
2. **C Oxynos** and FCW Wu. Oral tibolone combined with testosterone as a potential male contraceptive: Pharmacodynamic study examining additive effects in suppression of pituitary-testicular axis. Endocrine Abstracts March 2004, Vol.7.
3. **C Oxynos**, C Rajeswaran, and PE Belchetz. Pituitary sarcoidosis with disappearing mass: case report. Endocrine Abstracts March 2004, Vol.7.
4. **C Oxynos**, S Lines, P Sullivan et al. Audit: BP distribution in diabetes patients with and without nephropathy; comparison to NICE targets. Diabetic Medicine. April 2004. Vol 21 (Supp.2).
5. **C Oxynos**, N. Thakker, C Hewitt et al. Comparison between azoospermic responders and oligozoospermic non responders to sex steroidal contraception: a pharmacogenetics study examining the AR, CYP17, LH β and 5 α -reductase-2 genes. Endocrine Abstracts March 2003, Vol.5.
6. **C Oxynos**, JM Phillips, I Laing, F et al. Oral clathrate DHEA as a potential form of androgen replacement in hypogonadal men. A phase 2, open label, placebo - controlled parallel group pharmacokinetic study. Endocrine Abstracts, March 2002, Vol.3.
7. **C. Oxynos**, JW Kane, RA Anderson et al. Use of an ultrasensitive chemiluminescent assay to investigate adequacy of gonadotrophin suppression in men undergoing hormonal male contraception. Endocrine abstracts, March 2001 Vol. 1

8. **C Oxynos**. J Holland & FCW Wu. An uncommon cause of male hypogonadism. Journal of Endocrinology. November 2000, Vol. 167, Supplement.
9. **C Oxynos** & FCW Wu. Male hormonal contraception. Bailliere's Clinical Endocrinology & Metabolism. 2000. Vol 14. No 3, 473-487.

PUBLICATIONS:(Other)

1. C Rajeswaran, A Dawson, G Bonney, **C Oxynos**, V Nicholson, S Gilbey. Intussusception as a gastrointestinal complication of diabetes: case report and literature review. 2004 Vol 4 (6).
2. C Rajeswaran, **C Oxynos**, and PE Belchetz. The evolution of diabetes insipidus in a man with multiple pathology in the sacrum. Endocrine Abstracts March 2004, Vol.7.
3. {C Rajeswaran, **C Oxynos**, HJ Bodansky. Pre-hospital management of hypoglycaemia. Prevailing practise, cost and a suggested management model. Submitted to Diabetic Medicine, 2004}.

PRESENTATIONS: (International and National Meetings)

1. An unusual cause of acute renal failure in a patient with T2DM. KR Narayanan S Eliades N Torpey and **C Oxynos**. ABCD Meeting London 2007.
2. S Eliades K Narayanan and **Oxynos C**. Lipid measurements in Diabetes Comparison to NICE targets, Northern regional Diabetes Audit meeting, Durham Univ. Newcastle, October 2005.
3. Coyne PE Erukupalti R Narayanan K and **Oxynos C**. Diabetic Nephropathy: Are NICE targets met and what is the implied workload. Diabetes & Endocrinology reportment QEH Feb 2006
4. Mettayil J Narayanan K Oxynos C and Weaver JW. Management of hyperglycaemia in patients with AMI on CCU. . Diabetes & Endocrinology reportment QEH Feb 2006
5. **C Oxynos** and Wu FCW. Oral tibolone combined with testosterone as a potential male contraceptive: Pharmacodynamic study examining additive effects in suppression of pituitary-testicular axis. Poster presentation: 23rd Joint Meeting of the BES, Brighton, March 2004.
6. **C Oxynos**, C Rajeswaran, and PE Belchetz. Pituitary sarcoidosis with disappearing mass: case report. Poster presentation: 23rd Joint Meeting of the BES, Brighton, March 2004.
7. **C Oxynos**, S Lines, P Sullivan et al. Audit: BP distribution in diabetes patients with and without nephropathy; comparison to NICE targets. *Oral communication*. Diabetes UK APC, Birmingham March 2004.
8. AT Thein, C Rajeswaran, C Lee, **C Oxynos**, A Shetty, SG Gilbey. Maternal booking weight correlates better with fetal macrosomia than glycaemic control in overweight pregnant women with gestational diabetes. ADIPS, Perth, September 2003.
9. **C Oxynos**, N. Thakker, C Hewitt et al. Comparison between azoospermic responders and oligozoospermic non responders to sex steroidal contraception: a pharmacogenetics study examining the AR, CYP17, LH β and 5 α -reductase-2 genes. Poster presentation: 22nd Joint Meeting of the BES, Glasgow, March 2003.

10. **C Oxynos**, JM Phillips, I Laing, et al. Oral clathrate DHEA as a potential form of androgen replacement in hypogonadal men.– a phase 2, open label, placebo-controlled parallel group pharmacokinetic study. Poster presentation: 21st Joint Meeting of the BES, Harrogate, April 2002, American Endocrine Society 84th meeting, San Francisco June 2002, Congresso, Parma, November 2001.
11. **C Oxynos**, JW Kane, RA Anderson & FCW Wu. Use of an ultrasensitive chemiluminescent assay to investigate adequacy of gonadotrophin suppression in men undergoing hormonal male contraception. Poster presentation: 20th Joint Meeting of the British Endocrine Societies, Belfast, March 2001. Focus 2001, London.
12. **C Oxynos**. Seminar lecture: “DHEA replacement in men and women”. NWES meeting. Manchester, February 2001.
13. **C Oxynos**. “IV Bisphosphonates for the treatment of osteoporosis”. NW Diabetes/ Endocrine meeting, Belfast, May 2000.

CONFERENCES (last 5 years)

1. ECE 2018 (European Congress Endocrinology), Barcelona, May 2018.
2. ECE 2016 (European Congress Endocrinology), Munich, Germany 28-31 May 2016.
3. Cyprus/Hellenic Endocrine Society Conference 2016. Larnaca Cyprus May 14-15, 2016.
4. Easter Mediterranean Conference General Medicine (Royal College Physicians/MRCA-Cy), 21-22 Nov 2015, Limassol Cyprus.
5. ECE 2015 (European Congress Endocrinology), Dublin 16-20 May 2015.
6. ECE 2014 (European Congress Endocrinology), Wroclaw, Poland. May 3-7 2014.
7. Osteoporosis Conference 2014 (National Osteoporosis Society, UK) Birmingham UK 1-2 Dec 2014.

MEMBERSHIP

European Society of Endocrinology. Membership number 123351
Cyprus Endocrine Society. Vice President.